Acumen Pharmaceuticals, Inc.

Today, our Head of HR Julie Bockenstette presented at the LEAP HR: Life Sciences East Conference in Boston, sharing her journey in building strong, strategic business partnerships. Julie spoke about the evolving role of HR as a key driver of business outcomes and how aligning people strategy with company goals can help life sciences organizations grow with clarity and impact. Thank you LEAP HR for the opportunity to learn, connect and contribute to the conversation. 

All good things must come to an end, and while the Acumen team is sad to leave #AAIC25, it’s been a wonderful week of sharing knowledge and innovation in the #Alzheimer’s field. We’ll see you all next year!

It’s day 4 of #AAIC25 and it has been a great conference so far, filled with insightful conversations and great connections -- we would love to talk to you at booth #1441 if you want to stop by!

Today Erika Cline, PhD is presenting a poster on a nonclinical study evaluating the relative selectivity of sabirnetug targeting AβOs versus Aβ monomers at #AAIC25. You can view the poster in person at AAIC or on our website. Link: https://lnkd.in/gKDBJAe4

Thank you to everyone who attended our reception last night in beautiful Toronto at #AAIC25! The Acumen team has been grateful to connect with so many of our ALTITUDE-AD study sites and partners, it’s been wonderful to spend time in person with so many people dedicated to Alzheimer’s research and innovation.

Today Prajakta Dinesh Mangeshkar, MSc, MS is presenting a poster titled “ALTITUDE-AD: Cost savings using a pTau217 screening assay in an ongoing Phase 2 study of sabirnetug in early Alzheimer's disease” at #AAIC25. You can view the poster in person at AAIC or on our website. Link: https://lnkd.in/gKDBJAe4

We’re pleased to share our latest findings from our Phase 2 ALTITUDE-AD study and a nonclinical study of sabirnetug at the Alzheimer's Association® International Conference 2025! ➡️Visit our posters to learn more about: 🔹The use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug, which reduced total screening costs by ~40% across U.S. and Canadian sites 🔹A nonclinical study evaluating the relative selectivity of sabirnetug for amyloid beta oligomers (AβO), which showed sabirnetug achieved the highest binding affinities to AβO preparations among the monoclonal antibodies tested with minimal interaction with monomeric Aβ 🔗Don’t miss our posters at AAIC and read our press release for more details: https://lnkd.in/gGy8xrmN   #Alz #AlzheimersResearch #ClinicalTrials #AAIC25 #Sabirnetug #pTau217

Toronto, we’ve arrived! The Acumen team is officially ready for the #AAIC25 kickoff tomorrow. We look forward to engaging with everyone during an exciting week focused on #Alzheimers, stop by booth #1441 to meet the team!

🧠 💉After 111 years of failed attempts, two companies join to try to crack human biology's finest safe. The blood-brain barrier protects our minds from harm, but also prevents medicines from reaching their targets. For patients with Alzheimer's, Parkinson's, brain cancer, and countless other conditions, this barrier has meant watching treatments work everywhere except where they're needed most. Soon, that might change. Acumen Pharmaceuticals, Inc. and JCR Pharmaceuticals announced a $555 million partnership combining precision-targeted antibodies with breakthrough delivery technology that actually works. Their approach doesn't fight the barrier, but works with it, using the brain's own transport systems to ferry medicines across safely and effectively. The science is elegant: JCR's J-Brain Cargo technology has already proven itself in humans, with Japan approving the first brain-penetrating therapy for Hunter syndrome in 2021. It works by hijacking the barrier's transport system to get its cargo to the other side and into the brain. Now they're applying the same breakthrough to Alzheimer's, aiming to bring Acumen's antibody through the blood-brain barrier. This antibody targets only the most toxic proteins to maximize benefits and reduce side effects. This isn't just another drug development story, instead it might be the beginning of a new era where the brain becomes as medically accessible as any other. For millions of patients and families, that possibility represents hope grounded in proven science. Read the full deep-dive below to know how more about the science behind this breakthrough and how it could change everything about treating brain diseases. ---- 👋 Hi, I’m Darío. For more news on science 🔬 , biotech 🧬, pharma 💊, and more, follow and check my newsletter! I also offer services in scientific writing for all kinds of audiences, helping you make an impact by going from complex ideas to clear, compelling narratives.

We're proud to share that Acumen is a Silver Sponsor of the Alzheimer's Association®'s International Conference this year in Toronto! Visit our team at booth #1441 to learn more about our latest innovations and explore our poster presentations, details in the link below. We look forward to connecting with you at #AAIC25! Link to learn more: https://lnkd.in/gezCAXeS